CA-S27: A novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma
Article first published online: 6 AUG 2013
© 2013 Japanese Cancer Association
Volume 104, Issue 10, pages 1278–1284, October 2013
How to Cite
(Cancer Sci 2013; 104: 1278–1284
- Issue published online: 3 OCT 2013
- Article first published online: 6 AUG 2013
- Accepted manuscript online: 28 JUN 2013 02:58AM EST
- Manuscript Accepted: 18 JUN 2013
- Manuscript Revised: 17 JUN 2013
- Manuscript Received: 3 APR 2013
- Research Team Strengthening Grant
- National Genetic Engineering and Biotechnology Center
- Ministry of Health Labour and Welfare of Japan
- Grant-in-Aid for Science Research in a Priority Area from the Ministry of Education, Culture, Sports, Science and Technology
- Advanced Education Program for Integrated Clinical, Basic and Social Medicine
- Kumamoto University and the Program of Founding Research Centers
|cas12222-sup-0001-FigS1.tiff||TIFF image||4407K||Fig. S1. MUC5AC mucin was the major source of CA-S27 detected in serum.|
|cas12222-sup-0002-FigS2.tiff||TIFF image||3834K||Fig. S2. FUT3 was the major glycosyltransferase of cholangiocarcinoma (CCA) cell lines.|
|cas12222-sup-0003-FigS3.tiff||TIFF image||3291K||Fig. S3. S27-mAb decreased cholangiocarcinoma (CCA) cell proliferation by cell growth suppression but not apoptosis induction.|
Table S1. List of Primers and siRNA.
Table S2. Correlation of serum CA-S27 and clinical data of cholangiocarcinoma (CCA) patients.
Table S3. Glycosyltransferase expression profile of KKU-M213 and MMNK1.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.